The arrival of Retatrutide in the United Kingdom is generating significant buzz within the weight loss community. This innovative dual agonist – targeting both GLP-1 and GIP – promises a potentially new strategy to addressing weight challenges. Until recently, options have been constrained for many, and Retatrutide embodies a encouraging prospe